(HealthDay News) — Severe valvular heart disease (VHD) is prevalent among patients with cancer and is associated with reduced survival, according to a study presented at the annual congress of the ...

(HealthDay News) — Zoliflodacin is noninferior to ceftriaxone plus azithromycin for the treatment of uncomplicated urogenital gonorrhea, according to a study published online Dec. 11 in The Lancet.

The BigpAK-2 randomized prospective multicenter trial tested implementation of a bundle of measures to prevent acute kidney injury in high-risk patients undergoing major surgery. Trial results support ...

Biomarkers might improve risk stratification for patients with chronic kidney disease (CKD) at cardiovascular risk.

Investigators reported extended 5-year follow-up data from the CheckMate 274 trial including exploratory MIBC and circulating tumor (ct)DNA data.

Odds of vertebral compression fractures or surgical intervention were significantly lower among GLP-1 RA users.

Minimally invasive surgery linked to lower major complication risk, reduced length of stay, decreased transfusion rate.

(HealthDay News) — Among persons at high cardiovascular risk, there is low- to moderate-certainty evidence that reducing or modifying saturated fat intake can reduce mortality and major cardiovascular ...

Diagnostic evaluation should follow principle of 'as low as reasonably achievable'; systemic therapy should be deferred until second trimester.

The FDA has granted traditional approval to Rubraca (rucaparib) for metastatic castration-resistant prostate cancer.

FDA expands Accrufer approval to treat iron deficiency in pediatric patients aged 10 years and older based on phase 3 FORTIS trial outcomes.

Beyond hazard ratios, investigators used restricted mean survival time (RMST) analysis to compare survival gains across trialed ICI combinations for mRCC.